ReviewSchizophrenia (Heidelberg, Germany)2023
Pharmaco-EEG of antipsychotic treatment response: a systematic review.
Review in Schizophrenia (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Schizophrenia: Converging Neurobiological Mechanisms and Emerging Therapeutic Strategies.Biomolecules · 2026Review
- Comparison of the Utility of Amplitude-Spectral and Coherence Features of Psychotropic Drugs' Action on ECoG Signal for Pharmaco-EEG Based Drug Screening in Rats.Methods and protocols · 2026Article
- Brainwaves under medication: revealing class-specific neural signatures of psychotropic medication from 24,000 EEGs.EBioMedicine · 2026Article
- Alpha Frequency Dysrhythmia in Treatment-Resistant Schizophrenia: Associations with EEG Background Changes, Disorganized Symptoms, and Dissociation.Biomedicines · 2026Article
- Multimodal EEG-MRI Neuroimaging in Schizophrenia-A Systematic and Mechanistic Review.Journal of clinical medicine · 2026Review
- Diminished variability of alpha and beta band-limited power as a neural signature in schizophrenia.Translational psychiatry · 2026Article
- Uncovering putative neural mechanisms of neurotherapeutic impacts on EEG using the Human Neocortical Neurosolver.bioRxiv : the preprint server for biology · 2026Article
- High-density EEG study in patients with schizophrenia treated with cariprazine.The international journal of neuropsychopharmacology · 2026Article
- Correlation of frontal lobe electroencephalogram asymmetry and cognitive prognosis in schizophrenia.World journal of psychiatry · 2026Article
- A computational pipeline for a neurotransmitter-centric analysis of the effects of psychiatric medication on EEG spectral power.Frontiers in psychiatry · 2026Article
- The therapeutic effects of ketogenic diet, lacosamide, and combination therapy in children with refractory epilepsy.BMC pediatrics · 2025Article
- Moving toward precision and personalized treatment strategies in psychiatry.The international journal of neuropsychopharmacology · 2025Review
- Resting-state EEG and MEG gamma frequencies in schizophrenia: a systematic review and exploratory power-spectrum metanalysis.Schizophrenia (Heidelberg, Germany) · 2025Review
- Reduced temporal variability of cortical excitation/inhibition ratio in schizophrenia.Schizophrenia (Heidelberg, Germany) · 2025Article
- Deep multimodal representations and classification of first-episode psychosis via live face processing.Frontiers in psychiatry · 2025Article
- Human neuroimaging and antipsychotic neurobiology at millisecond temporal resolution.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Article
- Microstate D as a Biomarker in Schizophrenia: Insights from Brain State Transitions.Brain sciences · 2024Article
- EEG Techniques with Brain Activity Localization, Specifically LORETA, and Its Applicability in Monitoring Schizophrenia.Journal of clinical medicine · 2024Review
- Prospects of Electrocorticography in Neuropharmacological Studies in Small Laboratory Animals.Brain sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Response to antipsychotic medications (AP) is subjected to a wide and unpredictable variability and efforts were directed to discover predictive biomarkers to personalize treatment. Electroencephalography abnormalities in subjects with schizophrenia are well established, as well as a pattern of EEG changes induced by APs. The aim of this review is to provide a synthesis of the EEG features that are related to AP efficacy, including both pre-treatment signatures and changes induced by APs during treatment. A systematic review of English articles using PubMed, PsychINFO and the Cochrane database of systematic reviews was undertaken until july 2023. Additional studies were added by hand search. Studies having as an endpoint the relationship between AP-related clinical improvement and electroencephalographic features were included. Heterogeneity prevented a quantitative synthesis. Out of 1232 records screened, 22 studies were included in a final qualitative synthesis. Included studies evaluated resting-state and task-related power spectra, functional connectivity, microstates and epileptic abnormalities. At pre-treatment resting-state EEG, the most relevant predictors of a poor response were a change in theta power compared to healthy control, a high alpha power and connectivity, and diminished beta power. Considering EEG during treatment, an increased theta power, a reduced beta-band activity, an increased alpha activity, a decreased coherence in theta, alpha and beta-band were related to a favorable outcome. EEG is promising as a method to create a predictive biomarker for response to APs; further investigations are warranted to harmonize and generalize the contradictory results of reviewed studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.